Gamboa et al. showed that ACE-1 inhibitor (ramipril) increased ADMA levels in patients with kidney disease and appears to have been modulated by bradykinin (BK) during ACE-1 inhibition [65]. This evidence concerns the gene ACE and kidney disorder.